Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT05632445

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
DR. XAVIER FREIXA (from the registry)
Registry
  • NCT NCT05632445
Other papers using this trial's data
  • Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial JAMA cardiology, 2024-10-01 DOI, PubMed 39110427, PMC11307161 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05632445. Randomized; single masking; primary purpose diagnostic. Start 2019-05-01 (actual); primary completion 2019-06-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
Acronym
ADALA
Condition
Left Atrial Appendage Occlusion
Intervention (Drug)
Apixaban vs. DAPT
Lead sponsor
DR. XAVIER FREIXA (class: other)

Record details

Record id
cardio:ct-nct05632445
Content hash
c2256a2b85b5744ca214c856b6980bf3e2f4c7206e9efac997f33bfacf397bd5